Switching to Faricimab in Neovascular Age-related Macular Degeneration Resistant to Both Aflibercept and Ranibizumab

NCT06231121 · clinicaltrials.gov ↗

COMPLETED

Status

13

Enrollment

OTHER

Sponsor class

Conditions

Neovascular Age-related Macular Degeneration

Interventions

DRUG: Faricimab

Sponsor

Rigshospitalet, Denmark